Lung cancer trials in Portugal

In Portugal 43 Also abroad 2733

43 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Where
Coimbra, Lisbon, Porto, Senhora Da Hora
Age
18 years and over
People
780 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06312137 · EU 2023-508012-35-00
Phase 3Taking people
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
Where
Almada, Coimbra, Guimarães, Lisbon
Age
18 years and over
People
420 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07099898
Phase 3Taking people
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
Where
Braga, Coimbra, Lisbon, Porto
Age
18 years and over
People
670 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07472517 · EU 2025-520565-51-00
Phase 3Taking people
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Where
Coimbra, Lisbon, Porto
Age
18 years and over
People
1,000 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06561386 · EU 2024-513682-40-01
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
Where
Coimbra, Lisbon, Loures, Porto, Vila Nova de Gaia
Age
18 years and over
People
400 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07541170 · EU 2025-524263-21-01
Phase 3Taking people
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Where
Lisbon, Porto, Senhora Da Hora
Age
18 years to 100 years
People
750 worldwide
Run by
Amgen
See details and how to joinNCT05920356 · EU 2022-501863-41-00
Phase 3Taking people
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Where
Braga, Loures, Porto, Vila Nova de Gaia
Age
18 years and over
People
600 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06793215
Phase 3Taking people
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Where
Coimbra, Lisbon, Porto
Age
18 years and over
People
1,264 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06119581 · EU 2023-503412-33-00
Phase 3Taking people
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Coimbra, Lisbon, Porto, Senhora Da Hora
Age
18 years and over
People
444 worldwide
Run by
Bayer
See details and how to joinNCT06452277 · EU 2024-511319-91-00
Phase 3Taking people
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Where
Coimbra, Lisbon, Porto
Age
18 years and over
People
700 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06890598 · EU 2024-512302-25-00
Phase 3Taking people
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Where
Funchal, Lisbon, Matosinhos, Vila Nova de Gaia
Age
18 years and over
People
614 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06170788 · EU 2023-503376-24-00
Phase 2Taking people
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Where
Braga, Guimaraes, Lisbon, Loures, Porto, Vila Nova de Gaia
Age
18 years and over
People
480 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06667076 · EU 2025-520730-28-00
Phase 3Taking people
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Where
Lisbon, Porto
Age
18 years and over
People
400 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07195695 · EU 2025-521284-12-00
Phase 2/3Taking people
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Where
Coimbra, Guimaraes, Lisbon, Porto
Age
18 years and over
People
626 worldwide
Run by
Mirati Therapeutics Inc.
See details and how to joinNCT04613596 · EU 2023-508922-83-00
Phase 3Taking people
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Where
Lisbon, Porto
Age
18 years and over
People
768 worldwide
Run by
AbbVie
See details and how to joinNCT04928846 · EU 2023-505749-14-00
Phase 1Taking people
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
Where
Lisbon, Porto
Age
18 years and over
People
554 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT04886804 · EU 2024-511246-39-00
Phase 1/2Taking people
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Where
Braga, Lisbon
Age
18 years and over
People
248 worldwide
Run by
Terremoto Biosciences Inc.
See details and how to joinNCT07109726
Phase 3Taking people
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Where
Coimbra, Lisbon, Porto
Age
18 years and over
People
630 worldwide
Run by
Mirati Therapeutics Inc.
See details and how to joinNCT06875310 · EU 2024-515698-85-00
Phase 3Taking people
A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Cancer (NSCLC) after immunotherapy failure.
Where
Coimbra, Lisbon, Porto, Vila Nova de Gaia
Age
18 years and over
People
340 worldwide
Run by
OSE Immunotherapeutics
See details and how to join2023-509340-10-00 · EU 2023-509340-10-00
Phase 3Taking people
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Where
Lisbon, Porto
Age
18 years and over
People
686 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06899126 · EU 2024-515658-26-00
Phase 3Taking people
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Where
Braga, Lisbon
Age
18 years and over
People
750 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07361510 · EU 2025-523586-18-00
Phase 1Not yet taking people in Portugal
A phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors
Where
Porto
Age
18 years and over
People
64 worldwide
Run by
Novartis Pharma AG
See details and how to join2024-518348-19-00 · EU 2024-518348-19-00
Phase 2Taking people
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Where
Lisbon, Porto
Age
18 years to 95 years
People
630 worldwide
Run by
AstraZeneca
See details and how to joinNCT05061550 · EU 2023-508852-21-00
Phase 1/2Taking people
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Porto
Age
18 years and over
People
430 worldwide
Run by
Bayer
See details and how to joinNCT05099172 · EU 2023-503795-24-00
Phase 3Taking people
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Where
Braga, Loures, Porto, Vila Nova de Gaia
Age
18 years and over
People
282 worldwide
Run by
F. Hoffmann-La Roche AG
See details and how to join2024-518365-10-00 · EU 2024-518365-10-00